231 related articles for article (PubMed ID: 14739668)
1. A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
Jefford M; Michael M; Rosenthal MA; Davis ID; Green M; McClure B; Smith J; Waite B; Zalcberg J
Invest New Drugs; 2004 Apr; 22(2):185-92. PubMed ID: 14739668
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Sayar H; Shen Z; Lee SJ; Royce M; Rabinowitz I; Lee F; Smith H; Eberhardt S; Maestas A; Lu H; Verschraegen C
Invest New Drugs; 2009 Apr; 27(2):153-8. PubMed ID: 18773144
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; Semiond D; deJonge MJ; Eskens FA; ter Steeg J; Selleslach J; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
J Clin Oncol; 2005 Feb; 23(4):889-98. PubMed ID: 15681535
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Becerra CR; Verma UN; Tran HT; Tavana D; Williams NS; Frenkel EP
Am J Clin Oncol; 2008 Jun; 31(3):219-25. PubMed ID: 18525298
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Mazard T; Ychou M; Thezenas S; Poujol S; Pinguet F; Thirion A; Bleuse JP; Portales F; Samalin E; Assenat E
Cancer Chemother Pharmacol; 2012 Mar; 69(3):807-14. PubMed ID: 22037922
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Rea DW; Nortier JW; Ten Bokkel Huinink WW; Falk S; Richel DJ; Maughan T; Groenewegen G; Smit JM; Steven N; Bakker JM; Semiond D; Kerr DJ; Punt CJ
Ann Oncol; 2005 Jul; 16(7):1123-32. PubMed ID: 15939714
[TBL] [Abstract][Full Text] [Related]
8. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J
Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.
Tewes M; Schleucher N; Achterrath W; Wilke HJ; Frings S; Seeber S; Harstrick A; Rustum YM; Vanhoefer U
Ann Oncol; 2003 Sep; 14(9):1442-8. PubMed ID: 12954586
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies.
Goel S; Jhawer M; Rajdev L; Hopkins U; Fehn K; Baker C; Chun HG; Makower D; Landau L; Hoffman A; Wadler S; Mani S
Am J Clin Oncol; 2002 Oct; 25(5):528-34. PubMed ID: 12393999
[TBL] [Abstract][Full Text] [Related]
12. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
[TBL] [Abstract][Full Text] [Related]
14. A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
Han JY; Lee DH; Kim HY; Kim EA; Lee JJ; Ju SY; Shin EH; Lee JS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5909-14. PubMed ID: 14676114
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer.
Lorusso V; Crucitta E; Silvestris N; Guida M; Misino A; Latorre A; De Lena M
Clin Breast Cancer; 2003 Jun; 4(2):138-41. PubMed ID: 12864942
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
18. Phase one dose finding study of capecitabine (Xeloda), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer.
Stokes Z; Symonds P; Habeshaw T; Reed N; Curto J; Joynson C; Chan S
Gynecol Oncol; 2005 Jun; 97(3):790-5. PubMed ID: 15894361
[TBL] [Abstract][Full Text] [Related]
19. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.
Koizumi W; Kurihara M; Satoh A; Takiuchi H; Tanabe S; Shimada K; Iwasaki R; Saigenji K
Anticancer Res; 2005; 25(2B):1257-62. PubMed ID: 15865075
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
